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Abstract: Rationale: Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved to treat type 2
diabetes mellitus and obesity. GLP-1R agonists reduce airway inflammation and hyperresponsiveness
in preclinical models. Objectives: To compare rates of asthma exacerbations and symptoms between
type 2 diabetic adults with asthma prescribed GLP-1R agonists and those prescribed sodium-glucose
cotransporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, sulfonylureas or basal
insulin for diabetes treatment intensification. Methods: Electronic health records-based new-user, active
comparator, retrospective cohort study of patients with type 2 diabetes and asthma newly prescribed
GLP-1R agonists or comparator drugs, January 2000-March 2018. Primary outcome was asthma exac-
erbations; secondary outcome was encounters for asthma symptoms. Propensity scores were calculated
for GLP-1R agonist and non-GLP-1R agonist use. Zero-inflated Poisson regression models included ad-
justment for multiple covariates. Measurements and Main Results: Patients initiating GLP-1R agonists
(n=448), SGLT-2 inhibitors (n=112), DPP-4 inhibitors (n=435), sulfonylureas (n=2,253) or basal insulin
(n=2,692), were identified. At six months, asthma exacerbation counts were lower in persons initiating
GLP-1R agonists (reference) compared to SGLT-2 inhibitors (incidence rate ratio [IRR], 2.98 [95% CI,
1.30 to 6.80]), DPP-4 inhibitors (IRR, 2.45 [95% CI, 1.54 to 3.89]), sulfonylureas (IRR, 1.83 [95% CI, 1.20
to 2.77]) and basal insulin (IRR, 2.58 [95% CI, 1.72 to 3.88]). Encounters for asthma symptoms were also
lower among GLP-1R agonist users. Conclusions: Adult asthmatics prescribed GLP-1R agonists for type
2 diabetes had lower counts of asthma exacerbations compared to other drugs initiated for treatment
intensification. GLP-1R agonists may represent a novel treatment for asthma associated with metabolic
dysfunction.
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Running title: Asthma exacerbations in GLP-1R agonist users
Subject category list number: 1.11
Manuscript word count: 3,522
Impact: In this study of patients with asthma and type 2 diabetes, use of GLP-1R agonists for 
diabetes therapy was associated with fewer asthma exacerbations. These clinical, observational 
data build on preclinical data supporting a role for the GLP-1 metabolic pathway in asthma.  
This article has an online data supplement, which is accessible from this issue’s table of content 
online at www.atsjournals.org. 
At a Glance
What is the current scientific knowledge on this subject?
Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved to treat type 2 diabetes 
mellitus and obesity. GLP-1R agonists reduce airway inflammation and hyperresponsiveness in 
preclinical models.
What does this study add to the field?
In this study of patients with asthma and type 2 diabetes, use of GLP-1R agonists for diabetes 
therapy was associated with fewer asthma exacerbations. These clinical, observational data 
build on preclinical data supporting a role for the GLP-1 metabolic pathway in asthma.
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Abstract
Rationale: Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved to treat type 2 
diabetes mellitus and obesity. GLP-1R agonists reduce airway inflammation and 
hyperresponsiveness in preclinical models. 
Objectives: To compare rates of asthma exacerbations and symptoms between type 2 diabetic 
adults with asthma prescribed GLP-1R agonists and those prescribed sodium-glucose 
cotransporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, sulfonylureas or 
basal insulin for diabetes treatment intensification.
Methods: Electronic health records-based new-user, active comparator, retrospective cohort 
study of patients with type 2 diabetes and asthma newly prescribed GLP-1R agonists or 
comparator drugs at an academic healthcare system, January 2000-March 2018. Primary 
outcome was asthma exacerbations; the secondary outcome was encounters for asthma 
symptoms. Propensity scores were calculated for GLP-1R agonist and non-GLP-1R agonist use. 
Zero-inflated Poisson regression models included adjustment for multiple covariates.
Measurements and Main Results: Patients initiating GLP-1R agonists (n=448), SGLT-2 inhibitors 
(n=112), DPP-4 inhibitors (n=435), sulfonylureas (n=2,253) or basal insulin (n=2,692), were 
identified. At six months, asthma exacerbation counts were lower in persons initiating GLP-1R 
agonists (reference) compared to SGLT-2 inhibitors (incidence rate ratio [IRR], 2.98 [95% CI, 
1.30 to 6.80]), DPP-4 inhibitors (IRR, 2.45 [95% CI, 1.54 to 3.89]), sulfonylureas (IRR, 1.83 [95% 
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CI, 1.20 to 2.77]) and basal insulin (IRR, 2.58 [95% CI, 1.72 to 3.88]). Healthcare encounters for 
asthma symptoms were also lower among GLP-1R agonist users. 
Conclusions: Adult asthmatics prescribed GLP-1R agonists for type 2 diabetes had lower counts 
of asthma exacerbations compared to other drugs initiated for treatment intensification. GLP-
1R agonists may represent a novel treatment for asthma associated with metabolic 
dysfunction.
Abstract word count:  249
MeSH Keywords: anti-asthmatic agents, diabetes mellitus type II, electronic health records
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Introduction
Metabolic dysfunction represents a common and challenging comorbid asthma 
condition(1). Insulin resistance and metabolic syndrome are associated with asthma 
development(2, 3) and exacerbation risk(4). Among patients with asthma, those with higher 
BMI(5) or obesity(6) have higher medication and healthcare utilization and poor symptom 
control(7) suggesting that metabolic dysfunction contributes to asthma severity(8). Prior 
studies have shown that some medical therapies which improve insulin resistance (metformin, 
sulfonylureas) improve asthma control(9, 10). Limited observational data from patients with 
type 2 diabetes mellitus (type 2 DM) without respiratory disease, suggest that glucagon-like 
peptide-1 receptor (GLP-1R) agonists in combination with metformin may improve baseline 
pulmonary function(11). However, use of other diabetes therapies such as insulin and DPP-4 
inhibitors do not impact incident asthma risk(12, 13). Therefore, therapies targeting metabolic 
pathways may be key to achieving asthma control for a significant proportion of individuals 
with asthma(14). 
Glucagon-like peptide-1 (GLP-1) is a hormone stimulated by the ingestion of 
carbohydrates, fats, and proteins and secreted by the intestine and the central nervous system, 
thereby regulating metabolic, cardiovascular and neuroprotective activities(15, 16). GLP-1R 
agonists are FDA approved as part of a stepwise approach to treatment intensification beyond 
metformin for type 2 DM(17). As a class, the GLP-1R agonists potentiate insulin and suppress 
glucagon secretion in type 2 diabetics with low risk of hypoglycemia(18), decreased 
cardiovascular and renal risk(19) and lower all-cause mortality(20). GLP-1R signaling also 
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promotes weight loss through delayed gastric emptying and increased satiety(18) leading to 
FDA approval for weight management in euglycemic patients (17).
The GLP-1R is found in lung epithelial and endothelial cells(11) underscoring a possible 
role for GLP-1 signaling in pulmonary disease(21). Administration of GLP-1R agonists in 
preclinical murine(22) and ex vivo models(11) significantly inhibits allergic and viral airway 
inflammation, decreasing airway eosinophilia, mucus production, and hyperresponsiveness(23, 
24). However, the impact of GLP-1R agonist use on asthma exacerbations and asthma control 
(symptoms) in humans has not been assessed. 
We analyzed real-world data from the electronic health records (EHR) of a large 
academic US health system to determine whether initiation of GLP-1R agonist therapy was 
associated with decreased asthma exacerbations and asthma symptoms compared with 
initiation of other therapeutics used for treatment intensification of type 2 DM among patients 
with asthma. Some of the results of these studies have been previously reported in the form of 
an abstract(25).
Methods
Patients, Settings and Data Source
The study used patient data between January 1, 2000 to March 1, 2018 from the 
Partners’ Healthcare Research and Patient Data Repository (RPDR) that includes academic and 
community hospitals in the greater Boston, Massachusetts area. RPDR is a central data 
warehouse that stores clinical data across Partners Healthcare(26). Detailed medical record 
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data elements extracted in this study included: demographics, diagnoses, laboratory tests, 
health maintenance, medications, problem lists, weight, height and body mass index (BMI).  
Adult patients (≥18 years) meeting both asthma and type 2 DM definitions were 
included in the study (Figure 1). Asthma was defined as at least two separate encounters with a 
qualifying International Classification of Diseases (ICD) code or one asthma encounter with both 
a diagnosis code and an asthma medication prescription. Type 2 DM was defined as at least one 
encounter for type 2 DM or a hemoglobin A1c (HbA1c) value ≥6.5, and a type 2 DM medication 
prescription. From this cohort we excluded patients with ICD diagnosis codes for diseases 
commonly treated with systemic steroids, chronic congestive heart failure, vocal cord 
dysfunction, and other respiratory diseases except chronic obstructive pulmonary disease 
(COPD), which we examined in our analysis. We also excluded patients with > two distinct 
encounters with type 1 DM codes. Inclusion and exclusion ICD codes criteria can be found in 
Table E1 in the online data supplement. Similar algorithms for inclusion and exclusion criteria 
have been previously validated at multiple institutions(27-30). Patients with a medication 
prescription and an ICD coded encounter diagnosis have a high rate of EHR data 
“completeness” in this dataset(31). 
Study Design
We conducted a retrospective cohort study of routinely collected clinical data using a 
new user, active comparator design(32) to determine the association between GLP-1R agonist 
initiation and asthma outcomes. Active comparators included SGLT-2 and DPP-4 inhibitors, 
sulfonylureas and basal insulin (see Supplementary Table E2 for a complete listing of drug 
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names). Comparator drug classes were selected based on the American Diabetes Associations’ 
(ADA) guidelines for treatment intensification of type 2 DM beyond first line therapy with 
metformin, diet and exercise (17). This stepwise approach is tailored to achieve glycemic 
targets and prevent diabetes complications.
Diabetics achieving glycemic control on first-line metformin monotherapy are clinically 
distinct from those requiring second-line or combination therapy by ADA guidelines; therefore, 
metformin monotherapy was not included as an active comparator. Concurrent diabetes 
medications including metformin were allowed. Given the potential effects of metformin on 
asthma control(10), metformin was included as a covariate in the analysis.
Exposure to any active comparator was defined as one prescription for the medication. 
Individuals were followed for six months from date of drug initiation as depicted in Figure E1 in 
the online data supplement. Duration of follow up was informed by medication adherence 
patterns in real-world clinical practice(33-35). We required all patients to have met both 
asthma criteria and type 2 DM criteria before drug initiation and to be alive at end of follow-up.
The primary outcome was a count of asthma exacerbations defined as a systemic (oral 
or intravenous) corticosteroid prescription(36). Further prescriptions within 7 days of the initial 
prescription were considered a single exacerbation event(37). The secondary outcome was a 
count of ICD coded emergency department (ED), inpatient and outpatient encounters for 
cardinal asthma symptoms: dyspnea, shortness of breath, wheeze, or cough (see 
Supplementary Table E3)(36, 38). Exploratory outcomes included counts of prescriptions for 
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short-acting beta-agonists (SABA) in the same period and counts of routine encounters for 
asthma.
We calculated a propensity score representing the estimated probability of initiating a 
GLP-1R agonist versus an active comparator, for each participant(39). Baseline covariates 
included in the propensity score were: age, sex, race/ethnicity, year of drug initiation to 
account for drug availability, month of drug initiation categorized by regional seasons 
(December-February (Winter); March-May (Spring); June-August (Summer); September-
November (Fall)) to account for seasonality of exacerbations and symptoms, insurance type, 
annual income (estimated from zip code), concurrent metformin use, Elixhauser chronic disease 
comorbidities (40), co-morbid COPD, and moderate or severe chronic kidney disease (CKD 3-5; 
defined as eGFR<60)(17). Post-baseline covariates (e.g. post-drug initiation BMI and HbA1c) 
were not included(41). Propensity scores were then included as a covariate in zero inflated 
Poisson (ZIP) regression models. The relationships between covariates, exposure and outcome 
are modeled in a directed acyclic graph in the online supplement (Figure E2). 
For each participant, the six months follow-up period began at new type 2 DM drug 
initiation. We expected a low event rate of asthma exacerbations based on Centers for Disease 
Control and Prevention data(42). ZIP models are selected when the occurrence of the outcome 
is rare employing a regression procedure specifically designed to account for positively skewed 
integer-valued distributions with a high incidence of zeros. The ZIP model first calculates a 
dichotomous outcome: the odds of a subject belonging to a class that always scores 0 vs. 1 on 
the outcome, e.g. any asthma exacerbation using logistic regression (“zero model”). The model 
Page 10 of 54
 AJRCCM Articles in Press. Published October 14, 2020 as 10.1164/rccm.202004-0993OC 
 Copyright © 2020 by the American Thoracic Society 
then estimates the frequency of events (e.g. asthma exacerbation count) among subjects in the 
1 class using a Poisson distribution, providing a count estimate from which a rate ratio can be 
calculated, and treatment conditions compared (“count model”). ZIP models were constructed 
with covariate adjustment for multiple confounders including season of drug initiation, baseline 
asthma severity in the 12 months prior to type 2 DM drug initiation categorized as mild 
(controlled without medications or with SABA or leukotriene receptor antagonist) versus 
moderate/severe (requiring inhaled corticosteroid alone or in combination with any other 
controller agent) based on prescription drug classes adapted from the 2018 Global Initiative for 
Asthma guidelines(43), smoking status, concurrent metformin prescription, and COPD, defined 
as ≥ 2 encounters at or within the 12 months prior to drug initiation. Examining the presence of 
co-morbid COPD coding within this asthma cohort reflects the recognition that in clinical 
practice patients with asthma may have features compatible with COPD, as in asthma-COPD 
overlap (ACO)(44) and accounts for co-coding in EHR data (45). COPD-only patients were 
excluded from this cohort by the asthma phenotype definition. 
To test the robustness of the association between GLP-1R agonist use and asthma 
outcomes we added baseline BMI and HbA1c in the propensity score. Change in BMI and change 
in HbA1c over the follow-up period were included as covariates in the ZIP model as a sensitivity 
analysis. 
In an additional sensitivity analysis, we examined those patients with more than one 
prescription for the initiated drug during the study period. We examined the effect of 
prescriptions for any DM drugs in the year preceding the 6-month study period as covariates to 
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minimize confounding by longitudinal metabolic changes or order of treatment intensification. 
Patients with missing covariates were excluded from the sensitivity analyses. Each drug class 
has variable effect on weight and HbA1c, both of which may be associated with asthma, and 
therefore imputed data was not used in any analysis.
In a pre-specified exploratory analysis, we examined prescriptions for SABAs and 
routine, non-exacerbation encounters for asthma in the follow-up period, applying the same 
model constraints and covariates. We additionally tested whether the findings in our primary 
analysis were robust for the moderate/severe asthma subgroup and never smokers.
Statistical significance was accepted at a two-sided P-value of ≤ .05. Statistical analyses 
were performed in SAS version 14.3 Cary, NC, USA. The study was approved by the Partners 
Institutional Review Board (protocol #2017P001730) prior to data collection.
Results
After inclusion and exclusion criteria were applied, our cohort included 448 new 
initiations of GLP-1R agonists, 112 of SGLT-2 inhibitors, 435 of DPP-4 inhibitors, 2,253 of 
sulfonylureas, and 2,692 of basal insulin for a total of 5,940 new initiations among 4,373 
patients (Figure 1). Initiation did not differ by season across groups. Within the GLP-1R agonist 
class, liraglutide (53.1%) and exenatide (35.9%) were the most common drugs initiated. Table 1 
shows the baseline characteristics of patients by drug initiation. New users of GLP-1R agonists 
were more likely to be younger and female. Baseline asthma severity was similar across the 
groups supporting there was therapeutic balance with regards to baseline asthma status prior 
Page 12 of 54
 AJRCCM Articles in Press. Published October 14, 2020 as 10.1164/rccm.202004-0993OC 
 Copyright © 2020 by the American Thoracic Society 
to treatment intensification with GLP-1R agonists or comparators. 17% of asthma patients also 
had a prior encounter coded for COPD.
Analysis of Primary and Secondary Outcomes
For the primary outcome, asthma exacerbations within six months of drug initiation, 
GLP-1R agonist users had significantly fewer exacerbations compared to patients in all 
comparator groups in the multivariable count model (Table 2). As shown in Figure 2A, 
compared to GLP-1R agonist users, adjusted exacerbation rates were higher among SGLT-2 
inhibitor, DPP-4 inhibitor, sulfonylurea and basal insulin. GLP-1R agonist users also had fewer 
encounters for asthma symptoms than DPP4-inhibitor, basal insulin and sulfonylurea groups 
(Table 2; Figure 2B). Unadjusted counts in each treatment group and unadjusted rates are 
presented in Supplementary Table E4. There were similarly higher symptom counts among 112 
SGLT-2 inhibitor users that did not reach statistical significance. As metformin use was a 
predictor of fewer asthma exacerbations across groups, we included metformin as a covariate 
in the analysis; the effect of GLP-1R agonists on asthma exacerbations was independent of 
metformin. While GLP-1R agonist use was associated with decreased counts of exacerbations 
following initiation across all comparator groups, the odds of having zero exacerbations was 
increased by GLP-1R agonist use compared to DDP-4 inhibitor and insulin users, but not 
compared to sulfonylurea users or SGLT-2 inhibitor users (Supplementary Table E5). Odds of 
having zero encounters for asthma symptoms was not increased by GLP-1R agonist use across 
all groups.
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Sensitivity, Subgroup and Exploratory Analyses
In the propensity-score adjusted analysis inclusive of pre- and post-study period HbA1c 
and BMI values, GLP-1R agonist users had statistically significant lower asthma exacerbation 
counts compared to all comparator groups (Table 3). The odds of having no exacerbation were 
not increased by GLP-1R agonist initiation compared to DPP-4 inhibitor, sulfonylurea and insulin 
users; SLGT-2 inhibitor users had increased odds of zero exacerbations (Supplementary Table 
E6). Missing covariate data was evenly distributed across the newer diabetes drug classes 
including GLP-1R agonist, SGLT-2 and DPP-4 inhibitors. Comparatively, basal insulin and 
sulfonylurea classes had more missing BMI and HbA1c data. Patients missing any of these four 
values were excluded in this analysis. 
Among users with ≥ 2 prescriptions for a given study drug during the six months study 
period (n=1,548), GLP-1R agonist users still had fewer asthma exacerbations compared to DPP-
4 inhibitor (IRR, 2.31 [95% CI 1.08 to 4.91]; P = .03) and basal insulin (IRR, 2.88 [95% CI 1.63 to 
20.85]; P = .002) groups with trends observed in sulfonylurea (IRR, 1.81 [95% CI 0.92 to 3.56]; P 
= .09) and SGLT-2 inhibitor (IRR, 1.75 [95% CI 0.25 to 12.23]; P = .57) groups (Supplementary 
Table E7). 
The effect of GLP-1R agonists on asthma exacerbations was also independent of prior 
diabetes drug exposures across study groups. GLP-1R agonist users had fewer exacerbations 
compared to patients in all comparator groups in the count model including DPP-4 inhibitor 
(IRR, 2.51 [95% CI 1.58 to 3.98]; P = <.001), sulfonylurea (IRR, 1.84 [95% CI 1.21 to 2.78]; P = 
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.005), SGLT-2 inhibitor (IRR, 2.90 [95% CI 1.26 to 6.66]; P = .01), and basal insulin (IRR 2.64 [95% 
CI 1.76 to 3.98]; P = <.001) users.
The association between GLP-1R agonist use and decreased asthma exacerbations was 
robust in the moderate/severe asthma subgroup (Supplementary Table E8) despite a smaller 
sample size (n = 2,828). Among never smokers (n = 2,335) GLP-1R agonist users had fewer 
exacerbations compared to DPP-4 inhibitor, sulfonylurea, and basal insulin users but not SGLT-2 
inhibitor users which was limited by small sample size (n = 69) (Supplementary Table E9). 
We tested for the possibility of asthma medication non-compliance or degree of routine 
asthma healthcare utilization as drivers of asthma exacerbations. In exploratory analyses we 
found that there were no differences across groups compared to GLP-1R agonist users for 
routine asthma encounters or SABA prescriptions during the study period (Supplementary 
Table E10).
Discussion
In this EHR-based retrospective cohort study of asthmatic, type 2 diabetics requiring 
intensified type 2 DM therapy, those initiating GLP-1R agonists had fewer asthma exacerbations 
compared to those initiating alternate agents. There were no differences in baseline asthma 
severity across the groups and no difference in routine asthma care encounters during the 
study period. The propensity-score adjusted analysis accounted for important demographic 
confounders including sex, race/ethnicity as well as clinical confounders such as concurrent 
metformin use, seasonality, and smoking status. There were no differences in rate of drug 
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initiation by individual month or by regional season. This was robust when also accounting for 
changes in HbA1c and in BMI, suggesting that the observed association of GLP-1R agonists with 
decreased exacerbations is independent of improved glycemic control and weight loss. 
Our secondary outcome analysis suggests that GLP-1RA initiators also have reduced 
asthma symptoms. We excluded diagnostic mimics of asthma, strengthening the specificity of 
these symptoms even in the context of the metabolic syndrome(46). Studies have shown that a 
history of asthma, as established in our study cohort, significantly increases the positive 
predictive value (PPV) of asthma symptoms as indicative of poor asthma control in EHR (47) 
even in the setting of obesity(48). Standardized patient-reported asthma control questionnaires 
such as the Asthma Control Test and Asthma Control Questionnaire use symptoms of 
“shortness of breath” and “wheeze” to measure symptom control(49, 50). Patients on GLP-1R 
agonists had fewer associated encounters coded with these symptoms compared to basal 
insulin and sulfonylurea users. This is distinct from routine encounters for asthma, which do not 
necessarily indicate any symptomatic state. No difference in symptom burden was seen 
compared to the SGLT-2 inhibitor group; however, these users had greater systemic steroid 
exposures due to asthma exacerbations during the same period which may have improved 
symptom control. While we excluded other respiratory diseases from our patient sample, we 
cannot exclude the possibility that these symptoms may be confounded by another disease 
process, such as atherosclerotic cardiovascular disease, also ameliorated by GLP-1R agonist 
use(19). 
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Our data further suggest that GLP-1R agonists are associated with decreased 
exacerbation counts among patients with exacerbations, and particularly among the 
moderate/severe asthma subgroup, as GLP-1R agonist use was not consistently associated with 
increased odds of having zero exacerbations. This supports the observed clinical benefit of GLP-
1RA among those with a more severe asthma phenotype. As our sample included patients with 
a range of asthma severity, we expected a high proportion of zero counts and low mean counts 
of exacerbations. This resulted in a modest absolute reduction in exacerbation rates which has 
implications for study design and sample size calculations for future prospective studies. 
Although a minority of asthma patients in the study were co-coded for COPD, they were 
predominantly classified as having moderate/severe asthma in line with prior estimates(44). 
The presence of COPD patients in the moderate/severe asthma group may reflect the clinical 
use of ICD codes to capture ACO which lacks specific diagnostic ICD codes. Clinical studies have 
traditionally excluded these patients(44) and future research is needed to ascertain 
phenotyping of these patients in the EHR in addition to the underlying pathobiology, to 
examine the potential role of metabolic pathways and therapeutic targets(14). Early research 
suggests that metformin, a first line diabetes therapy, may be beneficial for ACO highlighting 
the potential relevance of metabolic pathways in this group and warranting further 
investigation in this field(51). As this study’s inclusion criteria only phenotyped asthma patients, 
excluding COPD-only patients, future research is needed to assess the impact GLP-1R agonist 
use on COPD-specific exposures and outcomes. 
Strengths of this EHR analysis are the inclusion of BMI and HbA1c data, clinically relevant 
covariates that may not be available in administrative datasets. The relationship of metabolic 
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dysfunction and asthma represents an area of active investigation(8, 52). Other studies using 
administrative data have found that anti-diabetic therapies variably impact asthma in the 
setting of metabolic dysfunction; metformin attenuating asthma exacerbation risk(9, 10), 
consistent with our findings, and basal insulin associated with incident asthma(12). However, 
these studies were limited in their ability to address the impact of clinical covariates on their 
primary outcomes. These analyses point to a therapeutic association of GLP-1R agonists 
independent of metformin use, baseline and change in BMI, and glycemic control. Future areas 
of research include examining synergistic effects of anti-diabetes therapy, such as metformin 
and GLP-1R agonists, on pulmonary outcomes. 
Limitations
This study relies on EHR data. EHR data are considered real-world data representing 
routine clinical care(39) that may be used to support supplementary indications for FDA-
approved medications(53). However, there is considerable heterogeneity in approaches to 
disease phenotyping of EHR data(54-58) for asthma and DM, and we chose stringent 
phenotypes to address this limitation. There is potential for unmeasured confounding in this 
analysis. To minimize this, we additionally excluded patients who might routinely receive 
steroids and did not include prescriptions for inhaled corticosteroids in our outcome definition, 
consistent with core outcome measures for clinical asthma trials. Despite these steps, we could 
not exclude systemic steroids prescribed for an indication other than asthma exacerbation. 
Similarly, data from the EHR reflects care sought by patients at sites within our health 
system. While our system is the largest in the region, and patients in this study met a high level 
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of data completeness(31), it is not a closed system and there is no mechanism in place to flag 
outcomes that occur elsewhere but are missing in our EHR.  Therefore, our outcome events 
may be underestimated across all drug exposures as patients may have sought care, particularly 
for acute episodes such as asthma exacerbations, at unaffiliated sites. 
Finally, we took several steps to address confounders stemming from possible 
mechanistic links between metabolic and pulmonary dysfunction. We required a complete 
clinical data set for a sensitivity analysis that included baseline HbA1c, baseline BMI and change 
in both parameters. The association for lower counts of asthma exacerbations among GLP-1R 
agonist users was robust across all the comparator groups, as previously discussed. Clinical data 
missingness was proportionally higher for basal insulin and sulfonylureas than the other three 
classes and we did not impute missing data. Missingness across years may be due to changes in 
EHR platforms or coding practice over time(39). Where weight and height were not both 
available at the same encounter, we carried forward height from prior visits to calculate BMI 
yet missing data for this important characteristic remains a weakness of this study. Insulin can 
be weight-promoting while GLP-1R agonists have a favorable weight loss profile. As obesity is 
associated with more poorly controlled asthma(6, 7) we cannot rule out residual confounding 
from weight in the basal insulin exposed population. 
Conclusions 
Among patients with asthma and type 2 diabetes requiring intensified type 2 DM 
therapy, those initiating GLP-1R agonists had lower counts of asthma exacerbations and asthma 
symptoms within six months of drug initiation compared to patients initiating other DM 
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medications. Prospective human studies to validate these findings and to understand the 
mechanism(s) of the GLP-1R in the airway are needed to support the clinical selection of GLP-1R 
agonists for patients with asthma, with and without comorbid metabolic dysfunction. 
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Figure Legends
Figure 1. Selection of Patients from Electronic Health Records (EHR).  Diagram depicts patient 
selection by EHR data as of March 2018. Some patients met more than one exclusion criteria. 
Final comparator groups included DPP-4 = dipeptidyl peptidase-4; GLP-1R = glucagon-like 
peptide-1 receptor; SGLT-2 = sodium–glucose cotransporter-2.
Figure 2. Incidence Rate Ratios and 95% CIs for Asthma Exacerbations and Asthma Symptom 
Encounters Among Patients with Type 2 Diabetes. Users of sodium–glucose cotransporter-2 
(SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, sulfonylureas and basal insulins 
were compared to glucagon-like peptide-1 receptor (GLP-1R) agonist users (reference group). 
A, GLP-1R agonist users have fewer asthma exacerbations compared to all comparator cohorts. 
Asthma exacerbations incidence rate ratios and 95% CIs are derived from zero inflated Poisson 
regression models. B, GLP-1R agonist users have fewer asthma symptoms compared to DPP-4 
inhibitor, sulfonylurea and basal insulin groups. Asthma symptom encounter incidence rate 
ratios and 95% CIs are derived from zero inflated Poisson regression models.
Page 32 of 54
 AJRCCM Articles in Press. Published October 14, 2020 as 10.1164/rccm.202004-0993OC 
 Copyright © 2020 by the American Thoracic Society 
























Age, Mean (SD) 54(12.5) 60(11.4) 63.5(12.2) 59.5(14.1) 58.4(15) <.001
Sex, No. (%)      <.001
  F 323(72.1) 66(58.9) 286(65.7) 1387(61.6) 1,751(65)
  M 125(27.9) 46(41.1) 149(34.3) 866(38.4) 941(35)
Race/ethnicity, No. (%)      <.001
  White/Caucasian 298(66.5) 87(77.7) 300(69) 1,434(63.6) 1,714(63.7)
  Black/African Amer 58(12.9) 13(11.6) 47(10.8) 299(13.3) 382(14.2)
  Hispanic/Latino 46(10.3) 5(4.5) 43(9.9) 259(11.5) 332(12.3)
  Asian 3(0.7) 2(1.8) 14(3.2) 76(3.4) 36(1.3)
  Other/unknown 43(9.6) 5(4.5) 31(7.1) 185(8.2) 228(8.5)
Insurance type, No. (%)      <.001
  Medicaid 46(10.3) 7(6.3) 27(6.2) 204(9.1) 263(9.8)
  Medicare 172(38.4) 38(33.9) 196(45.1) 913(40.5) 1,000(37.1)
  Self 16(3.6) 4(3.6) 27(6.2) 308(13.7) 398(14.8)
  Commercial 210(46.9) 63(56.3) 178(40.9) 809(35.9) 1,011(37.6)
  Other 4(0.9) 0(0) 7(1.6) 19(0.8) 20(0.7)
Annual income†, dollars      .01
  <30,000 10 (2.3) 2 (1.8) 13(3.1) 88(4.0) 104(4.0)
  30,000-100,000 379(85.6) 92(82.1) 359(84.5) 1,939(87.1) 2,307(87.0)
  >100,000 54(12.2) 18(16.1) 53(12.5) 198(8.9) 240(9.1)
Year of drug initiation, 
Average (SD) ‡ 2 013.6(2.9) 2 015.7(1.2) 2 013.1(2.8) 2 010.3(4.4) 2 011(4.2) <.001
Season§ of drug 
initiation, No. (%)      .21
Winter 95 (21.21) 16 (14.29) 107 (24.60) 517 (22.95) 658 (24.44)
Spring 129 (28.79) 42 (37.50) 114 (26.21) 644 (28.58) 786 (29.20)
Summer 109 (24.33) 32 (28.57) 110 (25.29) 529 (23.48) 621 (23.07)
Fall 115 (25.67) 22 (19.64) 104 (23.91) 563 (24.99) 627 (23.29)
Smoking status, No. (%)      <.001
  Current 45(10) 9(8) 40(9.2) 353(15.7) 402(14.9)
  Never 208(46.4) 69(61.6) 205(47.1) 889(39.5) 964(35.8)
  Prior 168(37.5) 34(30.4) 148(34) 645(28.6) 791(29.4)  
  Unknown 27(6) 0(0) 42(9.7) 366(16.2) 535(19.9)  
Chronic kidney disease 
(eGFR <60) ll, No. (%)      <.001
  N 434(96.9) 109(97.3) 398(91.5) 2 163(96) 2,514(93.4)  
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  Y 14(3.1) 3(2.7) 37(8.5) 90(4) 178(6.6)  
COPD**, No. (%)      <.001
  N 404(90.2) 107(95.5) 369(84.8) 1,907(84.6) 2,139(79.5)  
  Y 44(9.8) 5(4.5) 66(15.2) 346(15.4) 553(20.5)  
Asthma severity††, No. 
(%)      .13
  Mild (without recent 
medications) 160(35.7) 46(41.1) 153(35.2) 912(40.5) 1,040(38.6)  
  Mild (with recent 
medications) 77(17.2) 18(16.1) 63(14.5) 289(12.8) 354(13.2)  
  Moderate/Severe 211(47.1) 48(42.9) 219(50.3) 1,052(46.7) 1,298(48.2)  
Metformin use‡‡, No. 
(%)       <.001
  N 202(45.1) 57(50.9) 185(42.5) 936(41.5) 1,504(55.9)
  Y 246(54.9) 55(49.1) 250(57.5) 1,317(58.5) 1,188(44.1)  
Elixhauser score, Mean 
(SD) 3.3(2.2) 3.1(2.4) 3(2.5) 2.9(2.2) 3.4(2.5) <.001
BMI§§, Mean (SD) 39.5 (8.6) 34.7 (7.2) 34.4 (8.0) 35.4(8.5) 35.4 (10.5) <.001
HbA1c
 ll ll, Mean (SD) 8.4 (1.9) 8.2 (1.5) 8.1(1.6) 8.1 (1.8) 8.5 (2.2) <.001
Change*** in BMI, Mean 
(SD) -0.8 (2.7) -1(2.3) -0.2(8.7) -0.2(3.0) -0.5 (7.6) .14
Change††† in HbA1c, 
Mean (SD) -0.7 (1.6) -0.6 (1.1) -0.6(1.4) -0.8(1.8) -1.0 (2.1 ) .002
Light shading denotes included in propensity score. Dark shading denotes included in propensity score for the related sensitivity analysis only. 
For continuous variables the P value was calculated by one-way ANOVA; for categorial variables the P value was calculated by chi-square test.
*As of study drug initiation unless otherwise specified, for GLP-1R = glucagon-like peptide-1 receptor; SGLT-2 = sodium–glucose cotransporter-
2; DPP-4 = dipeptidyl peptidase-4. Drugs in each class detailed in the online data supplement Table E2. 
†Based on 5-digit zip code.
‡ Initial FDA approval for the newer diabetes classes include the following: GLP-1R agonists (2005), SGLT2-inhibitors (2013), DPP4-inhibitors 
(2006). Basal insulin and sulfonylurea classes were FDA approved before 2000.
§ December-February (Winter); March-May (Spring); June-August (Summer); September-November (Fall)
ll Defined as two or more International Classification of Diseases (ICD) codes for ESRD, chronic renal failure, or chronic kidney disease (CKD) 
stage 3-5 (eGFR <60) at or within 12 months before the initial prescription of study drugs.
** Defined as two or more encounters within 12 months prior to study drug initiation.
†† Defined by asthma medications prescribed within 12 months prior (“recent”) to study drug initiation: mild-patient meets asthma definition 
but no asthma medication prescriptions in the 12 months prior to study drug initiation, or only short-acting beta agonists (SABA) or only 
leukotriene receptor antagonists (LTRA); moderate/severe- patients receiving an inhaled corticosteroid prescription alone or in combination 
with other controllers or biologics.
‡‡Defined as a prescription within 90 days prior to study drug initiation.
§§ Defined as a measurement closest to initial drug prescription, range included within 365 days of study drug initiation up until 14 days post-
initiation.
ll ll Defined as a measurement closest to drug initiation, range included within 365 days of study drug initiation up until 14 days post-initiation.
*** Defined as the difference between baseline and end values. End BMI values included the measurement closest to the study end, range 
included 80 days from study drug initiation until 365 days post-study period end.
††† Defined as difference between baseline and end values. End HbA1c values included the measurement closest to the study end, range 
included 80 days from study drug initiation until 365 days post-study period end.
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Table 2. Primary and Secondary Asthma Outcomes*, by Type 2 Diabetes Treatment Groups
*Zero inflated Poisson regression model, count model (Poisson); both primary and secondary models reflect adjustment for significantly 
associated covariates including asthma severity, co-morbid chronic obstructive pulmonary disease, propensity score. The primary outcome 
model also reflects adjustment for metformin use which was negatively associated with exacerbations, but not symptoms.
† GLP-1R = glucagon-like peptide-1 receptor; SGLT-2 = sodium–glucose cotransporter-2, DPP-4 = dipeptidyl peptidase-4. Drugs in each class 
detailed in the online data supplement Table E2. 
 Asthma exacerbations Asthma symptoms
Treatment groups†
Incidence 
Rate Ratio 95% CI P value
Incidence 
Rate Ratio 95% CI P value
GLP-1R (n=448) ref   ref  
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Table 3. Sensitivity Analysis* for Asthma Exacerbations Outcome, Inclusive of Baseline and 
Change in Hemoglobin A1c (HbA1c) and Body Mass Index (BMI) 
 Asthma Exacerbations  
Treatment groups † Incidence Rate Ratio 95% CI P value
GLP-1R (n= 271)  ref  
SGLT-2 inhibitor (n= 74) 2.95 1.19 to 7.31 .02 
DPP-4 inhibitor (n= 224) 2.11 1.14 to 3.91 .02
Sulfonylurea (n= 1,007) 1.97 1.14 to 3.41 .02
Basal insulin (n= 1,015) 2.44 1.42 to 4.19 .001
*Zero inflated Poisson regression model, count model (Poisson); reflects adjustment for significantly associated covariates including co-morbid 
chronic obstructive pulmonary disease, metformin use, baseline HbA1c, change in BMI, propensity score. 
†GLP-1R = glucagon-like peptide-1 receptor; SGLT-2 = sodium–glucose cotransporter-2, DPP-4 = dipeptidyl peptidase-4. Drugs in each class 
detailed in the online data supplement Table E2. 
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20,591 patients met inclusion criteria for asthma and type 2 DM 
10,752,304 patients in electronic healthcare record (EHR) data repository 
8,252 patients met exclusion criteria* for 
 Asthma diagnosis mimics 
 Type 1 DM
4,746 asthmatic type 2 diabetics with study drug(s) initiations 
12,339 asthmatic, type 2 diabetics 
7,351 patients with new initiation of GLP-1R, SGLT-2 inhibitor, 
DPP-4 inhibitor, sulfonylurea or basal insulin 
2,605 did not meet asthma definition at start of drug initiation 
4,373 patients with eligible drug initiations; final cohorts listed by 
new drug initiations 
373 failed other inclusion criteria- 
 Without EHR data for full study period 
 Age <18y at study period start 
169,412 patients met asthma definition 163,454 patients met type 2 diabetes mellitus (DM) definition 
4,988 lack of study drug(s) initiation† 
448 new GLP-1R agonist users 112 new SGLT-2 inhibitor users 435 new DPP-4 inhibitor users 2,253 new sulfonylurea users 2,692 new basal insulin users 
†
Figure 1
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Online Data Supplement
Asthma Exacerbations in Type 2 Diabetics with Asthma on Glucagon-like Peptide-1 
Receptor Agonists
Dinah Foer, M.D.; Patrick E. Beeler, M.D.; Jing Cui, M.D., Ph.D; Elizabeth W. Karlson, 
M.D., M.S.; David W. Bates, M.D., M.Sc; Katherine N. Cahill, M.D.
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Table E4. Unadjusted Counts and Rates of Asthma Exacerbations, by Treatment Group
Table E5. Odds of No Asthma Exacerbation or No Asthma Symptom Encounter, by 
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Table E7. Asthma Exacerbations Among Initiators with More than One Prescription in 
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Table E8. Exploratory Analysis for Asthma Exacerbations for Moderate/Severe Asthma 
Subgroup, by Treatment Group
Table E9. Exploratory Analysis for Asthma Exacerbation in a Never Smoker Subgroup, 
by Treatment Group
Table E10. Exploratory Analysis for Asthma Encounters and Short-acting Beta Agonist 
Prescriptions, by Treatment Group
Figure Legend E1. Study Design
Figure Legend E2. Directed Acyclic Graph
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International Classification of Diseases (ICD)-9 and 
ICD-10 codes
Asthma 493.x, J45.x
Type 2 diabetes mellitus (DM) 250.x0,250.x2. 249.xx, E08.xx, E09.xx, E11.xx, O24.1x
Asthma drug classes Asthma drug names*
Anticholinergics alone Ipratropium bromide, tiotropium
Biologics Omalizumab
Inhaled corticosteroid
Beclomethasone, trimacinolone, fluticasone, 




Leukotriene modifiers Montelukast, zafirlukast, zileuton
Short acting beta agonists Albuterol, levalbuterol, albuterol-ipratropium bromide 
Type 2 DM drug classes Type 2 DM drug names*
Alpha glucosidase inhibitors Acarbose, miglitol
Amylin mimetic Pramlintide
Biguanides Metformin
Basal insulin Glargine, detemir, ultralente, degludec, lente, NPH 
DPP-4 inhibitor†, ‡, § Alogliptin, linagliptin, saxagliptin, sitagliptin, 
GLP-1R agonist ll Albiglutide, dulaglutide, exenatide, liraglutide
Meglitinides Nateglinide, repaglinide
SGLT-2 inhibitor ‡,** Canagliflozin, dapagliflozin, empagliflozin 
Sulfonylurea‡
Glimepiride, chlorpropamide, acetohexamide, 




Exclusion Diagnosis ICD-9 and ICD-10 codes
Type 1 diabetes 250.x1, 250.x3, E10.xx, O24.0x
Diseases impacting the respiratory system
Allergic bronchopulmonary aspergillosis 518.6
Alpha 1-antitrypsin deficiency 273.4, E88.01
Aspiration syndromes 934.8, T17.8x
Benign neoplasms of bronchus or lung 212.3, D14.3x
Bronchiectasis 494.xx, J47
Bronchopulmonary dysplasia 770.7, P22.0, P27
Cancers of lymphatic and hematopoietic 
systems 200.xx-208.xx, C81-C96, D45, E85
Cerebral palsy 343.x, G80.x
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Table E1, continued.
Congenital airway and lung abnormalities 748.2-748.9, Q31-Q34
Chronic pulmonary heart diseases 416.x, I27.x
Cystic fibrosis and metabolic disorders 277.xx, V77.6, V83.81, E84.x, E88.3, 
Disorders of diaphragm 519.4, J98.6
Extrinsic allergic alveolitis 495.x, J67
Lung involvement in other diseases classified 
elsewhere
517.x, D57.01, D57.01, D57.211, D57.411, 
D57.811, J17, J99
Motor neuron diseases 335.x, G12.x
Myopathies 359.x, G71.x, G72.x, G73.7
Pneumoconioses 500.x-508.x
Primary and secondary malignant neoplasm of 
airway, bronchus, lung or respiratory organs
160.xx to 165.xx, 197.0-197.3, C30-C34, 
C37- C39, C45, C78, J91.0
Pulmonary alveolar and parietoalveolar 
pneumonopathies 516.x, J84.x
Pulmonary fibrosis 515
Vocal cord and laryngeal disease 478.3x, 478.5, J38.0x, J38.2, J38.3
Disease often treated with systemic steroids
Inflammatory arthropathies 714.x, M05.XX, M06.xx, M08.xx, M12.xxx
Organ or tissue transplant
V42.x, V49.83, V58.44, E878.0, 996.8x, 
T86.x, Y83.0, Z48.2xx, Z76.82, Z94.x, Z95.3, 
Z95.4
Post-transplant lymphoproliferative disorder 238.77, D47.Z1
Systemic lupus erythematosus, scleroderma, 
systemic sclerosis, dermatomyositis 710.x, M32-M36
Other asthma mimics
Chronic congestive heart failure
428.XX, I50.22-23, I50.32-33, I50.42-43, 
I50.813, I50.84
*Agents available in the data set as of March 2018.
† Dipeptidyl peptidase-4.
‡ Includes formulations in combination with metformin.
§ Includes alogliptin formulation in combination with thiazolidinediones.
ll Glucagon-like peptide-1 receptor.
**Sodium-glucose costransporter-2.
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Table E2. Comparator Drugs Included in Study Design*
Drug class Drug names
Basal insulin Glargine, detemir, ultralente, degludec, lente, NPH 
DPP-4 inhibitor†
Alogliptin, alogliptin–metformin, linagliptin, linagliptin–metformin, 
saxagliptin, saxagliptin–metformin, sitagliptin, sitagliptin–metformin
GLP-1R agonist‡ Albiglutide, dulaglutide, exenatide, liraglutide
SGLT-2 inhibitor§
Canagliflozin, canagliflozin–metformin, dapagliflozin, dapagliflozin–
metformin, empagliflozin, empagliflozin–metformin,
Sulfonylurea
Glimepiride, chlorpropamide, acetohexamide, tolbutamide, glipizide, 
glyburide, tolazamide, glyburide-metformin, glipizide-metformin
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Table E3. Asthma Diagnoses and Medications Used for Outcome Definitions
Drug class Drug names*
Systemic (Oral and Intravenous) Steroids Prednisone, methylprednisolone, dexamethasone
Asthma symptom




Shortness of breath 786.05, R06.02
Wheezing 786.07, R06.2
*Drugs available in the data set as of March 2018.
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Table E4. Unadjusted Counts and Rates of Asthma Exacerbations, by Treatment 
Group





GLP-1R agonist (n=448) 0.17 (.58) ref ref
SGLT-2 inhibitor (n=112) 0.09 (.61) 0.53 2.98
DPP-4 inhibitor (n=435) 0.24 (.83) 1.42 2.45
Sulfonylurea (n=2,253) 0.22 (0.74) 1.27 1.83
Basal insulin (n=2,692) 0.33 (1.08) 1.93 2.58
*GLP-1R = glucagon-like peptide-1 receptor; SGLT-2 = sodium–glucose cotransporter-2, DPP-4 = dipeptidyl peptidase-4. Drugs in 
each class detailed in Table E2.
† For covariates in propensity score and zero-inflated Poisson model
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Table E5. Odds of No Asthma Exacerbation or No Asthma Symptom Encounter, 
by Treatment Group*










GLP-1R agonist (n=448) ref   ref   
SGLT-2 inhibitor (n=112) 1.91 6.77
2.21 to 
23.74 .001 0.46 1.58
0.63 to 
3.98 .33
DPP-4 inhibitor (n=435) 0.77 2.14
1.15 to 
4.00 .02 0.43 1.54
0.84 to 
2.81 .12
Sulfonylurea (n=2,253) 0.45 1.57
0.91 to 
2.71 .11 0.46 1.58
0.93 to 
2.68 .09
Basal insulin (n=2,692) 0.54 1.71
0.99 to 
2.93 .05 0.20 1.22
0.73 to 
2.02 .45
* Zero inflated Poisson (ZIP), zero model (logistic).
†GLP-1R = glucagon-like peptide-1 receptor; SGLT-2 = sodium–glucose cotransporter-2, DPP-4 = dipeptidyl peptidase-4. Drugs in 
each class detailed in Table E2.
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Table E6. Odds of No Asthma Exacerbation by Treatment Group, Inclusive of 
Baseline and Change in Hemoglobin A1c and Body Mass Index*
 Asthma exacerbations 
Treatment group † Estimate Odds Ratio 95% CI P value
GLP-1R agonist (n= 271) ref   
SGLT-2 inhibitor (n= 74) 1.73 5.64 1.5 to 21.21 .01
DPP-4 inhibitor (n= 224) 0.67 1.95 0.80 to 4.73 .14
Sulfonylurea (n= 1,007) 0.37 1.44 0.67 to 3.13 .35
Basal insulin (n= 1,015) 0.23 1.25 0.58-2.70 .56
*Zero inflated Poisson (ZIP), zero model (logistic). Baseline and change over follow up period as defined in Table 1.
†GLP-1R = glucagon-like peptide-1 receptor; DPP-4 = dipeptidyl peptidase-4. Drugs in each class detailed in Table E2. 
Page 47 of 54
 AJRCCM Articles in Press. Published October 14, 2020 as 10.1164/rccm.202004-0993OC 
 Copyright © 2020 by the American Thoracic Society 
Table E7. Asthma Exacerbations Among Initiators with More than One 
Prescription in Each Group During the Study Period, by Treatment Group*
Asthma Exacerbations 
Poisson model Logistic model 
Treatment group†
Incidence 

































*Zero inflated Poisson (ZIP), count (Poisson) and zero (logistic) models; reflects adjustment for significantly associated covariates of 
comorbid COPD and asthma severity. 
† GLP-1R = glucagon-like peptide-1 receptor; SGLT-2 = sodium–glucose cotransporter-2, DPP-4 = dipeptidyl peptidase-4. Drugs in 
each class detailed in Table E2.
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Table E8. Exploratory Analysis* for Asthma Exacerbations for Moderate/Severe 
Asthma Subgroup, by Treatment Group
Asthma Exacerbations 
Poisson model Logistic model 
Treatment group†
Incidence 





95% CI P 
value
GLP-1R agonist (n= 211) ref ref
SGLT-2 inhibitor (n= 48) 3.94
1.65 to 
9.42 .002 6.66 
1.67 to 
26.5 .007















*Zero inflated Poisson (ZIP), count (Poisson) and zero (logistic) models; reflects adjustment for significantly associated covariates of 
comorbid COPD.
†GLP-1R = glucagon-like peptide-1 receptor; SGLT-2 = sodium–glucose cotransporter-2, DPP-4 = dipeptidyl peptidase-4. Drugs in 
each class detailed in Table E2.
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Table E9. Exploratory Analysis for Asthma Exacerbations in a Never Smoker 
Subgroup, by Treatment Group
Asthma Exacerbations 
Poisson model Logistic model* 
Treatment group†
Incidence 





95% CI P 
value



























*Zero inflated Poisson (ZIP) count model. SGLT-2 inhibitor sample size was too small to calculate event odds in the logistic model. 
†GLP-1R = glucagon-like peptide-1 receptor; SGLT-2 = sodium–glucose cotransporter-2, DPP-4 = dipeptidyl peptidase-4. Drugs in 
each class detailed in Table E2.
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Table E10. Exploratory Analysis* for Asthma Encounters and Short-acting Beta 
Agonist Prescriptions, by Treatment Group














































*Zero inflated Poisson (ZIP), count (Poisson) model.
†GLP-1R = glucagon-like peptide-1 receptor; SGLT-2 = sodium–glucose cotransporter-2, DPP-4 = dipeptidyl peptidase-4. Drugs in 
each class detailed in Table E2.
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Figure E1. Study Design Data extracted from electronic health records generated 
between years January 2000-March 2018. Six-month study period begins at GLP-1R 
agonist or comparator drug new initiation. GLP-1R = glucagon-like peptide-1 receptor; 
SGLT-2 = sodium–glucose cotransporter-2; DPP-4 = dipeptidyl peptidase-4.
Figure E2.  Directed acyclic graph summary for variables considered in Table 1. Box 
A includes baseline variables associated with the exposure. Box B includes baseline 
variables identified as potential confounders, associated with both exposure and 
outcome (asthma exacerbation). Box C includes variables associated with the outcome.
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Figure E1. 
Inclusion and exclusion criteria applied
Cohort entry: GLP-1R agonist, SGLT-2 inhibitor, DPP-4 
inhibitor, sulfonylurea, or basal insulin initiation
Six-month follow up period, 
outcome assessment 
Covariate assessment for 
change in BMI and HbA1c
Baseline covariate 
assessment
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Baseline chronic kidney disease
Year of drug initiation
Season of drug initiation
Baseline asthma severity
Smoking status
Post-initiation BMI change 
Post-initiation HbA1c change 
Box B.
Box C.
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